- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Accenture Releases Report on What Patients Want
Accenture released a new report on product launches in the pharmaceutical industry, based on a survey of 8,000 patients in France, Germany, the UK, and the U.S., across eight therapeutic areas-immunology, cardiology, pulmonology, neurology, oncology, rheumatology, endocrinology, and eye disease. The report is designed to help pharma companies understand what will help enable them to launch new treatments successfully in a market characterized by more-complex specialty therapeutics, rising costs, and an intensified focus on value and outcomes.
Findings in the report include that brands are not major influencing factors when patients consider new pharmaceutical products; more than two-thirds (69%) of patients surveyed said the product’s benefits (i.e., treatment outcomes) are more important than the brand itself, with less than one-third (31%) citing a strong affinity to brands in a healthcare setting.
Based on survey findings, the report offers two major recommendations for pharma companies, 1) bring an outcome, not just a product, to market and 2) make it personal and precise.
View the full report here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
